Application of semiconductor blue laser in day surgery for 22 cases of bladder cancer
10.3969/j.issn.1009-8291.2023.02.007
- VernacularTitle:半导体蓝激光应用于膀胱肿瘤日间手术22例的初步体会
- Author:
Pengyi ZHENG
1
;
Jia GUO
1
;
Xiaopeng MEI
2
;
Yumei JIANG
1
;
Jinhai FAN
1
;
Lei LI
1
;
Qiang WANG
2
;
Dalin HE
1
;
Kaijie WU
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
2. Department of Anesthesiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
- Publication Type:Journal Article
- Keywords:
bladder cancer;
blue laser;
day surgery;
transurethral resection of cancer
- From:
Journal of Modern Urology
2023;28(2):119-121
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the feasibility and safety of semiconductor blue laser in the treatment of non-muscle invasive bladder cancer (NMIBC) in the day surgery model. 【Methods】 The clinical data of 22 NMIBC patients (average age 55.8 years and tumor size 1.4 cm) who underwent outpatient screening and accepted blue laser ambulatory surgery in our hospital during Jun.2022 and Sep.2022 were retrospectively analyzed. On the day of admission, transurethral resection of cancer was performed using blue laser en bloc enucleation. On the day of surgery or in the morning of next day, bladder irrigation was stopped, the catheter was removed, and patients were discharged. The baseline data, pre-hospital waiting time, operation time, length of hospital stay, hemoglobin decrease, complications and management, follow-up, medical costs, and patients’ satisfaction rate were recorded. 【Results】 The pre-hospital waiting time was 2 to 7 days, average (4.1±1.3)days. The operation time was 29 to 50 minutes, average (40.8±5.5)minutes. The length of hospital stay was 0.6 to 1.2 days, average (0.9±0.2)days. Hemoglobin decrease was 1 g/L to 8 g/L, average (3.8±1.8)g/L. The catheter was indwelt for 0.5 to 1 day, average (0.7±0.1)day. The medical costs were 13 790 to 16 811 Yuan, average (14 941.5±690.2) Yuan. Patients’ satisfaction rate was 100.0%. Mild intraoperative and postoperative complications occurred in 2 cases. One patient developed symptoms of cystitis which disappeared after 2 days of oral antibiotic cefixime, and another patient developed bladder spasm which was relieved after oral solifenacin succinate tablets. No adverse events such as obturator nerve reflex or bladder perforation occurred. After removal of the catheter, no urinary retention was observed. 【Conclusion】 This study was the first to apply blue laser ambulatory surgery in the treatment of bladder cancer, confirming that it is a safe, feasible, economical and efficient model for selected patients, which can be promoted in suitable hospitals.
